Plasma exchange for acute and acute-on-chronic liver failure: A systematic review and meta-analysis.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
03 Aug 2023
03 Aug 2023
Historique:
received:
31
03
2023
accepted:
20
07
2023
pubmed:
2
8
2023
medline:
2
8
2023
entrez:
2
8
2023
Statut:
aheadofprint
Résumé
Plasma exchange (PE) is a promising therapeutic option in patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). However, the impact of PE on patient survival in these syndromes is unclear. We aimed to systematically investigate the use of PE in patients with ALF and ACLF compared with standard medical therapy (SMT). We searched PubMed/Embase/Cochrane databases to include all studies comparing PE versus SMT for patients ≥ 18 years of age with ALF and ACLF. Pooled risk ratios (RR) with corresponding 95% CIs were calculated by the Mantel-Haenszel method within a random-effect model. The primary outcome was 30-day survival for ACLF and ALF. Secondary outcomes were overall and 90-day survival for ALF and ACLF, respectively. Five studies, including 343 ALF patients (n = 174 PE vs. n = 169 SMT), and 20 studies, including 5,705 ACLF patients (n = 2,856 PE vs. n = 2,849 SMT), were analyzed. Compared with SMT, PE was significantly associated with higher 30-day (RR 1.41, 95% CI 1.06-1.87, p = 0.02) and overall (RR 1.35, 95% CI 1.12-1.63, p = 0.002) survival in ALF patients. In ACLF, PE was also significantly associated with higher 30-day (RR 1.36, 95% CI 1.22-1.52, p < 0.001) and 90-day (RR 1.21, 95% CI 1.10-1.34, p < 0.001) survival. On subgroup analysis of randomized controlled trials, results remained unchanged in ALF, but no differences in survival were found between PE and SMT in ACLF. In conclusion, PE is associated with improved survival in ALF and could improve survival in ACLF. PE may be considered in managing ALF and ACLF patients who are not liver transplant (LT) candidates or as a bridge to LT in otherwise eligible patients. Further randomized controlled trials are needed to confirm the survival benefit of PE in ACLF.
Identifiants
pubmed: 37530812
doi: 10.1097/LVT.0000000000000231
pii: 01445473-990000000-00219
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Polson J, Lee WM. AASLD position paper: The management of acute liver failure. Hepatology. 2005;41:1179–1197.
Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology . 2013;144:1426–1437.
Abdallah MA, Waleed M, Bell MG, Nelson M, Wong R, Sundaram V, et al. Systematic review with meta-analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure. Aliment Pharmacol Ther. 2020;52:222–232.
Karvellas CJ, Leventhal TM, Rakela JL, Zhang J, Durkalski V, Reddy KR, et al. Outcomes of patients with acute liver failure listed for liver transplantation: a multicenter prospective cohort analysis. Liver Transpl. 2023;29:318–330.
Chris-Olaiya A, Kapoor A, Ricci KS, Lindenmeyer CC. Therapeutic plasma exchange in liver failure. World J Hepatol. 2021;13:904–915.
Kapoor D. Molecular adsorbent recirculating system: albumin dialysis-based extracorporeal liver assist device. J Gastroenterol Hepatol. 2002;17(Suppl 3):S280–S286.
Sokolov AA, Rey SI, Aleksandrova IV, Popov AV, Gendel LL, Gubanova SN, et al. Comparison of selective plasma exchange and plasmadialfiltration with MARS and Prometheus systems in the treatment of liver failure. Messenger Anesthesiol Resusc. 2020;17:39–52.
Clemmesen JO, Kondrup J, Nielsen LB, Larsen FS, Ott P. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol. 2001;96:1217–1223.
Khamri W, Abeles RD, Hou TZ, Anderson AE, El-Masry A, Triantafyllou E, et al. Increased expression of cytotoxic T-lymphocyte-associated protein 4 by T Cells, induced by B7 in Sera, reduces adaptive immunity in patients with acute liver failure. Gastroenterology. 2017;153:263–276.e268.
Tan EXX, Wang MX, Pang J, Lee GH. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. World J Gastroenterol. 2020;26:219–245.
Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64:69–78.
Ramakrishnan S, Hans R, Duseja A, Sharma RR. Therapeutic plasma exchange is a safe and effective bridge therapy in patients with alcohol-associated ACLF not having immediate prospects for liver transplantation-A case-control, pilot study. J Clin Apher. 2022;37:553–562.
Stahl K, Busch M, Fuge J, Schneider A, Manns MP, Seeliger B, et al. Therapeutic plasma exchange in acute on chronic liver failure. J Clin Apher. 2020;35:316–327.
Kumar SE, Goel A, Zachariah U, Nair SC, David VG, Varughese S, et al. Low volume plasma exchange and low dose steroid improve survival in patients with alcohol-related acute on chronic liver failure and severe alcoholic hepatitis-preliminary experience. J Clin Exp Hepatol. 2022;12:372–378.
Swaroop S, Arora U, Biswas S, Manas Vaishnav, Piyush Pathak, Ankit Agarwal. Therapeutic plasma-exchange improves short-term, but not long-term, outcomes in patients with acute-on-chronic liver failure: A propensity score-matched analysis. J Clin Apher. 2022;38:376–389.
Maiwall R, Sarin SK. Plasma Exchange in Acute and Acute on Chronic Liver Failure. Semin Liver Dis. 2021;41:476–494.
Shen Y, Wang XL, Wang B, Shao JG, Liu YM, Qin Y, et al. Survival benefits with artificial liver support system for acute-on-chronic liver failure: A time series-based meta-analysis. Medicine (Baltimore). 2016;95:e2506.
Alshamsi F, Alshammari K, Belley-Cote E, Dionne J, Albrahim T, Albudoor B, et al. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. Intensive Care Med. 2020;46:1–16.
Li G, Zhang P, Zhu Y. Artificial liver support systems for hepatitis B virus-associated acute-on-chronic liver failure: A meta-analysis of the clinical literature. Journal of Viral Hepatitis. 2023;30:90–100.
Mohamed MMG, Osman A, El-Halawany H. Plasma exchange for patients with acute or acute on chronic liver failure; meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2022;46:102014.
Sundaram V, Shah P, Wong RJ, Karvellas CJ, Fortune BE, Mahmud N, et al. Patients with acute on chronic liver failure grade 3 have greater 14-day waitlist mortality than status-1a patients. Hepatology. 2019;70:334–345.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Stroup DF. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283:2008–2012.
Willis BH, Riley RD. Measuring the statistical validity of summary meta-analysis and meta-regression results for use in clinical practice. Stat Med. 2017;36:3283–3301.
Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353–390.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463.
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406.
Kim JE, Chun S, Sinn DH, Kim NJ, Kim S, Kang W, et al. Initial experience with high-volume plasma exchange in patients with acute liver failure. J Clin Apher. 2021;36:379–389.
Stahl K, Hadem J, Schneider A, Manns MP, Wiesner O, Schmidt BMW, et al. Therapeutic plasma exchange in acute liver failure. J Clin Apher. 2019;34:589–597.
Qin G, Shao JG, Wang B, Shen Y, Zheng J, Liu XJ, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore). 2014;93:e338.
Xia Q, Dai X, Huang J, Xu X, Yang Q, Liu X, et al. A single-center experience of non-bioartificial liver support systems among Chinese patients with liver failure. Int J Artif Organs. 2014;37:442–454.
Maiwall R, Bajpai M, Singh A, Agarwal T, Kumar G, Bharadwaj A, et al. Standard-Volume plasma exchange improves outcomes in patients with acute liver failure: A randomized controlled trial. Clin Gastroenterol Hepatol. 2022;20:e831–e854.
Mao W, Ye B, Lin S, Fu Y, Chen Y, Chen Y. Prediction value of model for end-stage liver disease scoring system on prognosis in the acute on chronic liver failure patients with plasma exchange treatment. Asaio j. 2010;56:475–478.
Al Mahtab M, Al Mamun A, Khondaker FA, Moben AL, Akbar SM, Das DC, et al. Plasma exchange in patients of acute on chronic liver failure: an observational study in Bangladesh. Euroasian J Hepatogastroenterol. 2022;12:1–5.
Wu C, Peng W, Cheng D, Gu H, Liu F, Peng S, et al. Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis b liver failure. J Clin Transl Hepatol. 2023;11:433–440.
Yang Z, Zhang Z, Cheng Q, Chen G, Li W, Ma K, et al. Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients. Hepatol Int. 2020;14:491–502.
Yang L, Wu T, Li J, Xin J, Shi D, Jiang J, et al. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: a case-control matched analysis. Hepatol Res. 2020;50:656–670.
Ye JL, Ye B, Lv JX, Mao WL, Gu B. Changes of ammonia levels in patients with acute on chronic liver failure treated by plasma exchange. Hepatogastroenterology. 2014;61:141–145.
Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol. 2008;23:1242–1249.
Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462–469.
Chen Y, Li H, Xu B, Zheng X, Li B, Wang X, et al. Plasma exchange-based non-bioartificial liver support system improves the short-term outcomes of patients with Hepatitis B Virus-associated acute-on-chronic liver failure: A multicenter prospective cohort study. Front Med (Lausanne). 2021;8:779744.
Maiwall R, Bajpai M, Choudhury AK, Kumar A, Sharma MK, Duan Z, et al. Therapeutic plasma-exchange improves systemic inflammation and survival in acute-on-chronic liver failure: a propensity-score matched study from AARC. Liver Int. 2021;41:1083–1096.
Du WB, Li LJ, Huang JR, Yang Q, Liu XL, Li J, et al. Effects of artificial liver support system on patients with acute or chronic liver failure. Transplant Proc. 2005;37:4359–4364.
Fan Z, EnQiang C, Yao DL, LiBo Y, Hong L, Lang B, et al. Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system. PLoS One. 2017;12:e0175332.
Liu H, Zhang Q, Liu L, Cao Y, Ye Q, Liu F, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Artif Organs. 2020;44:E434–E447.
Xiao LL, Xu XW, Huang KZ, Zhao YL, Zhang LJ, Li LJ. Artificial liver support system improves short-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a propensity score analysis. Biomed Res Int. 2019;2019:3757149.
Chung RT, Stravitz RT, Fontana RJ, Schiodt FV, Mehal WZ, Reddy KR, et al. Pathogenesis of liver injury in acute liver failure. Gastroenterology. 2012;143:e1–e7.